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Abstract 13 
Telomeres are progressively eroded during repeated rounds of cell division due to the end 14 
replication problem but also undergo additional more substantial stochastic shortening 15 
events. In most cases, shortened telomeres induce a cell-cycle arrest or trigger apoptosis, 16 
although for those cells which bypass such signals during tumor progression, a critical length 17 
threshold is reached at which point telomere dysfunction may ensue. Dysfunction of the 18 
telomere nucleoprotein complex can expose free chromosome ends to the DNA double 19 
strand break (DSB) repair machinery, leading to sister-chromatid telomere fusions, inter-20 
chromosomal telomere fusion with both telomeric and non-telomeric loci. The consequences 21 
of telomere fusions in promoting genome instability have long been appreciated through the 22 
breakage-fusion-bridge (BFB) cycle mechanism, although recent studies using high 23 
throughput sequencing technologies have uncovered evidence for involvement in a wider 24 
spectrum of genomic rearrangements including chromothripsis. A critical step in cancer 25 
progression is the transition of a clone to immortality, through the stabilization of the 26 
telomere repeat array. This can be achieved via the reactivation of telomerase, or the 27 
induction of the alternative lengthening of telomeres (ALT) pathway. Whilst telomere 28 
dysfunction may promote genome instability and tumor progression, by limiting the 29 
replicative potential of a cell and enforcing senescence, telomere shortening can act as a 30 
tumor suppressor mechanism. However, the burden of senescent cells has also been 31 
implicated as a driver of aging and age-related pathology, and in the promotion of cancer 32 
through inflammatory signaling. Considering the critical role of telomere length in governing 33 
cancer biology, we review questions related to the prognostic value of studying the dynamics 34 
of telomere shortening and fusion, and discuss mechanisms and consequences of telomere-35 
induced genome rearrangements.  36 
  37 
Introduction  38 
Telomeres play a fundamental role in maintaining eukaryotic genome integrity by ensuring 39 
that the natural ends of chromosomes are not mistakenly recognized as double stranded DNA 40 
breaks (DSB) and processed by DNA repair pathways [1]. The highly-conserved telomere 41 
repeat tract found at the ends of human chromosomes consists of tandem repeats 42 
(TTAGGG)n, terminating with a 3ʹ overhang that is created via nucleolytic degradation [2-4]. 43 
This 3ʹ overhang undergoes strand invasion into the repeat array, assembling into a higher 44 
order chromatin structure that consists of a t-loop and telomere-associated protein 45 
components including the shelterin complex (TRF1 and TRF2, POT1, TIN2, RAP1 and TPP1) [5, 46 
6]. This specialized structure represses DNA damage signaling, preventing activation of the 47 
ATM and ATR kinases which may otherwise induce a cell cycle arrest and promote DNA repair 48 
(Fig.1) [7-10].   49 
Due to the inability of the DNA replication machinery to fully replicate linear DNA (the end 50 
replication problem), telomeres progressively shorten with each cell division [11, 12]. 51 
Telomeres may be elongated by the telomerase complex which consists of the catalytic 52 
reverse trascriptase TERT subunit and TERC, the RNA template from which TERT can actively 53 
add telomere repeats to the chromosome terminus [13-16]. Whilst TERC is expressed widely, 54 
TERT expression is downregulated in somatic cells leading to progressive telomere shortening 55 
[13-15]. 56 
In most cells, very short telomeres lead to senescence and cell cycle arrest [17]. In humans, 57 
this is thought to represent a fundamental tumor suppressor mechanism which limits the 58 
proliferative capacity of a cell, whilst also preventing genome instability that may arise from 59 
telomere dysfunction [5, 11]. This mechanism appears to be more common in long-lived and 60 
larger organisms, with mice, for example, possessing considerably longer telomeres than 61 
humans, and telomerase activity appearing to be less stringently regulated in mouse somatic 62 
cells [18-21]. Curiously in humans, both excessively long and short telomeres have been 63 
associated with increased cancer rates, suggesting there is a sweet spot for mean telomere 64 
length in preventing oncogenesis [22]. The mechanism by which longer telomere length leads 65 
to increased cancer risk remains unclear although it is plausible that setting telomere length 66 
too long, permits an increased replicative lifespan for a cell which extends the window over 67 
which transformation may occur. On the other hand, excessively short telomeres may drive 68 
too many cells into senescence, increasing the odds of bypassing this barrier and leading to 69 
telomere dysfunction. Additionally, senescent cells have further deleterious effects on the 70 
tissue-microenvironment through the acquisition of a senescence-associated secretory 71 
phenotype (SASP) which can promote tumor progression through proinflammatory signaling 72 
[23-25]. 73 
In human somatic cells in which DNA damage checkpoints are compromised, continued cell 74 
division and consequent telomere loss past the point at which senescence normally occurs, 75 
leads to a phase known as ‘crisis’ that is characterized by telomere uncapping, subsequent 76 
fusion events, and widespread genome instability [26, 27]. The dynamic loss and gain of whole 77 
chromosomes or segments of DNA is an early occurrence in cancer progression and is thought 78 
to be crucial for generating diversity in premalignant clones and driving oncogenic 79 
transformation through natural selection [28]. Possession of a genetic signature that confers 80 
a fitness advantage over a competitor leads to clonal expansion, and reiteration of this 81 
process can lead to a clonal cell population with a radically altered genetic profile, exhibiting 82 
oncogene overexpression and disrupted regulation of tumor suppression pathways [28]. 83 
Crucially, an emerging tumor-initiating clone requires the activation of a telomere length 84 
maintenance pathway in order to escape crisis, which is only achieved through either 85 
reactivation of telomerase found in around 85 - 95 % of cancers, or through elongation of 86 
telomeres via the ALT pathway [29-34]. 87 
This review is focused on telomere length dynamics in the context of cancer progression. We 88 
discuss how telomere dysfunction can lead to the evolution of an immortalized clonal 89 
population of cells with a radically altered karyotype and disrupted oncogene or tumor 90 
suppressor pathways. Additionally, the prognostic potential of telomere length or dysfunction 91 
is considered, and how this can be utilized to improve and personalize patient treatment 92 
course. 93 
 94 
Telomere length dynamics  95 
Telomere length is a species-specific trait that shows considerable variability between 96 
individuals as well as between tissues and across different chromosome arms [19, 35, 36]. In 97 
humans, telomere length is to a large extent genetically determined and shows a high degree 98 
of heritability with correlations between mother-offspring telomere length and a positive 99 
association with paternal age [37, 38]. Typically ranging in size from 5 - 12 kb in early 100 
adulthood, cross-sectional studies indicate that differences in telomere length among 101 
somatic tissues are established largely in the first two decades of life, which is thought to echo 102 
the underlying developmental program of the tissue [39]. 103 
The length of telomeres is carefully regulated with recent studies pointing to a telomere 104 
trimming mechanism involving telomeric zinc finger-associated protein (TZAP) that sets an 105 
upper limit on telomere length [40, 41]. At shorter telomeres TZAP is outcompeted for binding 106 
by TRF1 and TRF2, although diluted binding of these shelterin components at longer 107 
telomeres allows binding of TZAP and promotion of telomere trimming [42]. Each 108 
chromosome may also display its own characteristic length profile and distinctions are often 109 
observed between different alleles within the same cell giving rise to a bimodal population of 110 
telomeres at a given chromosome end [36, 43]. Inter-allelic differences have been observed 111 
as large as 6.5 kb in normal fibroblasts underlining the potential heterogeneity of telomere 112 
lengths within a single cell [36]. 113 
 114 
In somatic stem cells and some immune cells, telomerase activity is detectable at low levels, 115 
however this activity is clearly insufficient to maintain telomere length as progressive 116 
telomere losses are observed during aging [14, 15, 44]. In most cells, telomerase insufficiency 117 
or silencing leads to progressive telomere erosion of the order of 50 – 100 bp per cell division, 118 
or at the tissue level around 24 ± 7 bp per year in leukocyte, muscle, skin and fat cells [29, 39, 119 
45]. By adulthood, rates of telomere erosion show strong intra-individual synchrony 120 
irrespective of the proliferative demands of the tissue, which implies that attrition rates in 121 
stem cell populations are relatively consistent among tissues and proliferative demand is met 122 
through expansion of progenitor cells rather than increased stem cell division [39].  123 
In vitro, subsets of telomeres have been observed with lengths far below the sample mean, 124 
consistent with a rapid deletion of the repeat array. These stochastic events were observed 125 
with a frequency of around 4 % at the XpYp telomere resulting in telomeres with a length < 126 
2.32 standard deviations below the sample mean with potentially dysfunctional 127 
characteristics [36, 43]. Interestingly, cells with grossly shortened telomeres did not 128 
accumulate over time suggesting those cells had exited the cell-cycle, repaired their 129 
telomeres, or telomere fusions had occurred preventing further detection [36, 43]. However, 130 
it is unclear to what extent rapid telomere shortening occurs in vivo and whether it plays a 131 
role in driving genomic instability and pathology. 132 
 133 
Telomere crisis and escape 134 
In cell culture, telomere crisis can be induced by ablation of shelterin components such as 135 
TRF2, or by overexpression of a dominant-negative telomerase construct (DN-hTERT), 136 
followed by prolonged cell culture to induce replicative telomere erosion [46, 47]. DN-hTERT 137 
expression is thought to more closely resemble in vivo conditions during tumor development, 138 
although a drawback of the system is that escape may be achieved by a reduction in 139 
overexpression of the vector, in the absence of more biologically relevant events such as a 140 
gain in copy number of wild-type telomerase, or the release of epigenetic repression. 141 
Initially, continual passage of cells that lack functional telomerase leads to progressive erosion 142 
of telomere length and a concomitant increase in the variance of the distribution consistent 143 
with random cell division and exponential growth [26]. However, as telomeres shorten past 144 
a critical threshold the growth kinetics begin to change marking the inception of crisis, a state 145 
characterized by high numbers of senescent cells, morphological changes, reduced doubling 146 
rate, high levels of cell death through apoptosis or necrosis, and widespread genome 147 
instability [48, 49]. During this period, telomere fusions may also be detected, involving 148 
telomere-telomere events or joins with other genomic loci [26, 50, 51]. As crisis progresses, 149 
growth may cease entirely and remain that way indefinitely or until all cells have perished 150 
[26]. Escape from crisis is then only achieved through reactivation of telomerase, or through 151 
the ALT pathway [29-33]. 152 
Recurrent point mutations in the promoter of TERT have been identified in a range of cancers, 153 
with an overall frequency of around 19 %, although some cancers show a higher incidence 154 
[52-58]. Multiple transcription factor families have binding sites at the TERT promoter and 155 
several studies suggest that the chromatin environment plays a role in telomerase 156 
reactivation [59-61]. A G-quadruplex motif was recently found to play a role in maintaining 157 
repressive chromatin at the TERT promoter through the action of metastatic suppressor 158 
nonmetastatic 2 (NME2) protein, which appeared to mediate recruitment of silencing factors 159 
[60]. Large scale structural variation including balanced rearrangements, translocations and 160 
focal, high level amplifications has also been documented at the TERT locus in a subgroup of 161 
high-risk neuroblastoma patients suggesting that remodeling of genomic context may lead to 162 
release of transcriptional silencing [61]. 163 
Telomere stabilization by the ALT pathway relies on homologous recombination to elongate 164 
telomeres through a mechanism that is thought to resemble repair by the break-induced 165 
replication (BIR) pathway [30, 62-64]. Somatic mutations in the alpha-thalassemia X-linked 166 
syndrome protein (ATRX), histone variant H3.3, and the death associated protein (DAXX) have 167 
been identified in ALT positive cancers [65, 66]. The consequences of elongation of telomeres 168 
by ALT differs to the actions of telomerase in several respects. ALT cells tend to display a 169 
highly heterogeneous telomere length profile with both short and very long telomeres 170 
possible within a single cell [67]. Fluctuating telomere lengths and frequent exchange 171 
between sister chromatids have also been observed [68, 69]. Additionally, ALT cells exhibit 172 
APBs (ALT-associated promyleocytic leukemia bodies) and C-circles - extensive extra-173 
chromosomal telomere repeats which consists of partially single stranded circles of C-strand 174 
DNA derived from telomeres [70, 71]. Interestingly, ALT-elongated telomeres continue to 175 
experience replicative erosion and so periodic rounds of recombination may be required to 176 
maintain immortality, or, ALT tumors may recourse to reactivation of telomerase.  177 
The interplay of these two pathways are also beginning to be explored with recent studies 178 
suggesting that telomerase may play an important role in ALT inhibition, with the implication 179 
that antitelomerase therapies may inadvertently promote ALT induction [72, 73].   180 
 181 
Telomere fusions  182 
Telomeres that lack sufficient protection from the DSB repair machinery may undergo fusions 183 
with other telomeres in a head-to-head orientation or with other non-telomeric genomic loci 184 
following an additional genomic break. By studying the structure of telomere fusions at the 185 
nucleotide level, recent studies indicate that the classical and alternative non-homologous 186 
end joining pathways (C-NHEJ and A-NHEJ, respectively) play a central role in mediating these 187 
joins [47, 51, 74-76].  188 
The C-NHEJ pathway typically mediates blunt-end ligation, involving the high affinity binding 189 
of Ku proteins to either side of the break which promotes interaction with the X-Ray Cross 190 
Complementing: DNA ligase IV complex (XRCC4:LIG4) to catalyze the join [75, 77-79]. C-NHEJ 191 
is a high flux pathway that is responsible for repairing the bulk of cellular DSBs, with fusions 192 
characterized by low levels of breaksite processing and random levels of microhomology at 193 
the join. Although C-NHEJ can join a broad spectrum of breaks, the structure of some DNA 194 
ends present a problem for this pathway. In particular, breaks with single strand overhangs 195 
bind only weakly to the Ku recognition factors, inhibiting repair by the C-NHEJ pathway and 196 
thereby favoring A-NHEJ repair [80]. The A-NHEJ pathway exhibits a trend towards increased 197 
levels of microhomology and end resection at breaksites [75, 81, 82], and employs DNA 198 
polymerase θ, a mutagenic polymerase that can generate templated insertions at breaksites 199 
[83]. End joining by the A-NHEJ pathways is performed primarily by DNA-Ligase III (LIG3), 200 
although DNA-Ligase I (LIG1) may also be utilized in some cases [51, 84, 85].  201 
We have investigated the consequences of deficiencies in A- and C-NHEJ in mediating 202 
telomere fusions by the knockout of ligases LIG3 and LIG4 (LIG3-/-, LIG4-/-). In the context of 203 
DN-hTERT overexpression to drive cells into crisis, wild type and LIG4-/- cells displayed 204 
telomere fusions during crisis and readily escaped, though LIG4-/- cells displayed a reduction 205 
in the number of inter-chromosomal events between the 17p and XpYp telomere [26, 51]. 206 
Strikingly, LIG3-/- cells also displayed telomere fusions but were uniformly unable to escape 207 
crisis, with the entire culture perishing within 2 to 3 months [26]. Interestingly, LIG3-/- cells 208 
showed a significantly higher proportion of inter-chromosomal events (17p to XpYp fusions) 209 
relative to wild-type and LIG4-/- cells. 210 
These studies suggested that telomere fusions effected by the C-NHEJ pathway may therefore 211 
be more deleterious to the cell, presumably due to increased numbers of inter-chromosomal 212 
events which constitute a more severe disruption to the genetic and epigenetic landscape. 213 
Conversely, telomere fusion mediated via the A-NHEJ pathway may provide a selective 214 
advantage during crisis by favoring intra- or sister chromatid rearrangements that may result 215 
in localized amplification or deletion events. These observations raise the possibility of 216 
selectively targeting the A-NHEJ pathway during cancer progression to preclude the escape 217 
from crisis. 218 
Although less studied, homologous recombination (HR) pathways may also play a role in 219 
telomere fusions. In cells lacking the shelterin components TRF2 and RAP1, the homologous 220 
recombination factors PARP1 and SLX4 promoted resection of telomeres resulting in 221 
widespread telomere-free fusions involving nearly 50 % of chromosome ends [86]. We 222 
hypothesize that additional pathways such as the BIR pathway may also mediate telomere 223 
fusions at short dysfunctional telomeres, possibly driven by template switching events 224 
through the microhomology mediated break induced replication (MMBIR ) mechanism [87], 225 
although this remains to be investigated directly . 226 
Whilst the end joining pathways that mediate telomere fusions are beginning to be 227 
elucidated, characterizing the end-processing that occurs prior to repair has received less 228 
attention. From sequencing the breaksites of end-to-end telomere fusions it is apparent that 229 
sister chromatids can be differentially processed with one sister chromatid often undergoing 230 
a deletion event before joining [50, 51]. The longer chromatid often showed telomeric repeats 231 
but was joined with the shorter chromatid, several kb, into the sub telomere region, with 232 
greater distances obscured by limitations of the assay [26, 50, 51, 88]. These observations 233 
indicate that one of the sister chromatids was subjected to rapid resection prior to joining, 234 
although alternative mechanisms and means of repair cannot be ruled out. 235 
Telomere fusions have been shown to involve loci throughout the genome although the 236 
factors which govern where a fusion may occur remain poorly understood [51]. There is an 237 
expectation that chromatin accessibility and potentially transcriptional activity at a specific 238 
locus, will increase the probability of a telomere fusion due to the increased likelihood of 239 
provision of a DSB fusion partner for the dysfunctional telomere at these loci. Additionally, 240 
the organization of chromatin within the nucleus may play a role by favoring repair between 241 
local DSB ends. Other genomic features such as non-B-form DNA secondary structures, fragile 242 
sites or interstitial telomere repeats may also potentially enhance the occurrence of telomere 243 
fusions, and the stage of the cell cycle may further constrain the types of events that may 244 
arise [88, 89].  245 
 246 
Telomere fusions as drivers of genome instability 247 
Complex genome rearrangements can occur early during the progression to maligancy, 248 
preceding the invasive and metastatic stage of the disease, and are evident by the time 249 
telomerase expression is detected [90-92]. Telomere driven genome instability is considered 250 
to be intimately linked to oncogenesis by fostering clonal diversity and evolution of the 251 
genome through copy number gains or losses, genome reorganization and chromatin 252 
remodeling effects [93]. Investigating the consequences of telomere fusions on genome 253 
architecture therefore provides insight into the mechanisms which govern cancer 254 
progression. 255 
Dysfunctional telomeres can be fused with other loci in various configurations giving rise to 256 
sister chromatid, intra- or inter-chromosomal events. As replicative erosion occurs in parallel 257 
at all 92 telomeres of the cell, telomere dysfunction and telomere induced DNA damage 258 
signaling may occur rarely in isolation and instead may arise simultaneously at multiple ends. 259 
Additionally, the inception of telomere dysfunction may be most likely immediately following 260 
the telomere losses that occurs during DNA replication, when a dysfunctional telomere will 261 
be spatially prearranged with a sister chromatid with similar, potentially dysfunctional 262 
characteristics. Fusions between sister chromatids in end-to-end joining events are thus 263 
predicted to be more prevalent than inter-chromosomal end-to-end events, although 264 
limitations with current analysis techniques make this assumption difficult to prove [50, 88, 265 
94]. In the TRF2 knockdown model to induce telomere dysfunction, fusions were found to 266 
predominate between acrocentric chromosomes (chromosomes possessing a centromere 267 
located near the end of the chromosome), creating stable dicentric chromosomes 268 
(chromosome with two centromeres) that persisted for months in cell culture, although it is 269 
unclear if this finding extends to models of telomere dysfunction driven by replicative erosion 270 
[95]. 271 
Dicentric chromosome formation is one potential consequence of telomere fusion events. 272 
They can be unstable structures that may be broken during mitosis and initiate further rounds 273 
of fusion and breakage, leading to a cycle of events in what is known as Breakage-Fusion-274 
Bridge (BFB) cycle [27, 96](Fig. 2). Dicentric chromosomes can additionally arise from 275 
telomere fusions with non-telomeric genomic loci, though with the additional consequence 276 
of creating an acentric chromosome which may induce further genomic rearrangements and 277 
instability [97]. Rupture of the conjoining sequence between the two centromeres at mitosis 278 
can lead to several classes of rearrangements including deletions, duplications and 279 
translocations. Extended BFB cycling can generate extremely convoluted genome 280 
rearrangements and are often invoked to explain the amplified inverted repeats seen in solid 281 
tumors [98-101](Fig. 2).  282 
The genomic context of breakage during a BFB cycle is poorly defined, and may depend on 283 
several factors relating to the local chromatin environment through fragility effects, or may 284 
be related to sequence context or the presence of DNA lesions and modifications [102, 103]. 285 
In yeast, dicentric breakage occurs during cytokinesis with cleavage occurring preferentially 286 
at both the pericentromeric region and intriguingly at the initiating telomere fusion site [104]. 287 
Thus, yeast appear to have some capacity to recover their normal karyotype in the event of a 288 
telomere-telomere fusion, although it is unknown if this mechanism exists in humans. 289 
Another possible consequence of a telomere fusion is the creation of a non-reciprocal 290 
translocation that results in the transfer of the distal portion of one chromosome arm to the 291 
dysfunctional telomere, or the partial copy of one chromosome by the break-induced 292 
replication pathway [105, 106]. This transfer potentially reinstates a functional telomere at 293 
the initiating chromosome whilst the participating chromosome is left with a free end that 294 
may undergo repair with another locus, raising the possibility of a cascade of events which 295 
may only be terminated by the formation of a dicentric or circular chromosome, or the 296 
seeding of a new telomere at the free end, potentially via a recombination event (Fig. 2). Thus, 297 
the progressive genomic instability fostered by BFB cycling over extended cell generations is 298 
thought to partly underlie the highly-rearranged genomes seen in cancer [27, 107]. 299 
However, several groups have recently raised the prospect that telomere-induced genome 300 
instability may have an immediate and even more spectacular consequence on the integrity 301 
of the genome, by instigating a genome catastrophe - a whole genome restructuring event 302 
that occurs in a single step [101, 108-110](Fig. 2). Several classes of genome catastrophe have 303 
been proposed which ostensibly describe the differing genomic architectures and patterns 304 
identified, including chromothripsis, chromoplexy and chromoanasynthesis [108-112]. 305 
Chromothripsis is by far the most widely reported pattern, and is thought to arise from a 306 
chromosome shattering event that effects one or multiple chromosome arms [108]. 307 
Chromosome fragments are thought to undergo random ligation with concomitant loss of 308 
some fragments, giving rise to a shuffled pattern interspersed by regions showing loss of copy 309 
number or loss of heterozygosity [112]. Recently, the phenomenon of chromothripsis was 310 
reported in RPE1 cells following TRF2 knockdown to induce telomere dysfunction [113]. 311 
Tantalizingly, dicentric bridges were seen frequently in cells during crisis, and sequencing of 312 
post-crsis clones with abnormal karyotypes revealed a high incidence of chromothripsis, 313 
suggesting that chromothripsis may arise during dicentric bridge resolution at mitosis (Fig. 2). 314 
 315 
Telomere length as a prognostic marker in cancer 316 
The promotion of large scale genome rearrangements and instability by telomere dysfunction 317 
has been well documented [51, 114-118]. Telomere shortening which leads to these events 318 
is an early event during neoplastic progression [118-122]. These findings have led to 319 
significant interest as to whether telomere length could be used as a prognostic marker to 320 
determine clinical outcome in cancer [119, 123]. 321 
Chronic Lymphocytic Leukemia (CLL) has provided an exemplar of the use of telomere length 322 
measurements to define prognosis. CLL has a heterogeneous clinical course with overall 323 
survival ranging from a few months to many decades [124]. A multitude of clinical markers 324 
now exist for CLL including disease stage, patient age and performance status to numerous 325 
molecular markers such as immunoglobin gene mutational status, cytogenetics, CD38 326 
expression and ZAP70 expression [125, 126]. Although each marker used alone can give an 327 
indication as to what happens to a subset of patients none can give a definitive individual 328 
prognosis for a patient [127]. However, the use of high-resolution telomere length analysis 329 
identified telomere shortening and an increase in frequency of telomere fusion events during 330 
CLL progression [118]. Importantly, a subset of severely shortened telomeres, and associated 331 
telomere fusions, were also found in early-stage patient samples, indicating that these events 332 
precede disease progression [119]. Concomitant with telomere dysfunction in CLL patients 333 
with shorter telomeres, was the occurrence of large-scale genome rearrangements that were 334 
concentrated at telomeric regions [118]. Importantly, this was not observed in patients with 335 
longer telomeres. The telomere dynamics observed in CLL B cells was indistinguishable from 336 
cells undergoing crisis in culture following abrogation of the p53 pathway [118].  337 
The telomere length, below which telomere fusion was detected, was established in CLL B-338 
cells. This ‘fusogenic’ range was then used to stratify patients into favorable and unfavorable 339 
prognosis categories, even in early stage patients [119]. Patients with telomeres above the 340 
fusogenic mean showed superior prognosis regardless of their IGHV mutation status or 341 
cytogenetic risk group. In keeping with these findings, telomere length was the dominant 342 
variable in multivariate analysis [119, 123]. Telomere length has also been shown to be 343 
superior to established and recently discovered genomic biomarkers for predicting prolonged 344 
progression free survival following chemotherapy [123]. Taken together, these findings 345 
demonstrate telomere length as a powerful prognostic and predictive marker for CLL. 346 
Interestingly, use of this fusogenic range prognostic tool also appears to successfully stratify 347 
patients into favorable and unfavorable disease progression categories in breast cancer 348 
[128]. When a similar approach was performed in a cohort of tumor samples isolated from 349 
patients with invasive ductal carcinoma of the breast, a subset of patients was identified 350 
with a mean telomere length less than the fusogenic threshold. This subset of patients 351 
displayed a poor clinical outcome with a median survival of less than 12 months, compared 352 
to patients with longer telomeres who showed 89 % survival at 60 months. This telomere 353 
length threshold was independent of other predictive markers used in breast cancer 354 
including ER, PGR, HER2 status, NPI, or grade, and was the dominant variable in multivariate 355 
analysis demonstrating the prognostic power of telomere length in this cancer type [128]. 356 
Other cancers for which short telomere length can be used as a prognostic indicator include 357 
non-small cell lung cancer, myelodysplastic syndromes (MDS) and multiple myeloma [129-358 
132]. This finding was particularly striking in Multiple Myeloma considering median telomere 359 
length was measured from a mixed population of cells extracted from bone marrow [131]. 360 
The contribution of the myeloma CD138+ plasma cell subsets with shorter telomere-length 361 
profiles, within the mixed population was sufficient to reduce mean telomere length and 362 
allow prognostic discrimination [131]. 363 
The above examples are consistent with the idea of telomere length loss and subsequent 364 
dysfunction as being a precursor to tumor progression. Other studies indicate that the 365 
converse may be true, where for some cancers, longer telomere length predicts poor clinical 366 
outcome [133-139]. This has been demonstrated in oesophageal cancer where patients with 367 
a relative telomere length (RTL) greater than 1.22, as measured qPCR, have a shorter median 368 
survival time than patients with an RTL under this threshold [133]. 369 
Poorer clinical prognosis has been seen in patients with longer leukocyte telomere lengths for 370 
a number of cancers: in prostate cancer long telomere length was found to be an independent 371 
negative factor for both metastasis-free survival and PC-specific death when evaluated 372 
together with established risk factors (tumor stage, Gleason score, and serum PSA) [134]. 373 
Similar findings were also observed in breast, kidney, melanoma and hepatocellular 374 
carcinoma patients where patients with long leukocyte telomere length displayed a poorer 375 
outcome [135-139]. These findings on leukocyte telomere length however, do not necessarily 376 
conflict with the model of short dysfunctional telomeres in the developing tumor clone, 377 
driving tumor progression through the generation of large scale genomic instability and 378 
subsequent clonal evolution. Instead an ‘immunohypothesis’ has been put forward, 379 
suggesting that longer leukocyte telomere length may arise in patients with a suppressed 380 
immune system, leading to fewer cell divisions and reduced telomere shortening [133]. In 381 
support of this hypothesis, a significant correlation between leukocyte telomere length and 382 
peripheral levels of immunosuppressive regulatory T cells (Tregs) has been found in kidney 383 
cancer patients and hepatocellular carcinoma [138, 140]. 384 
U-shaped associations have also been observed between telomere length and cancer 385 
progression. In a recent case-control study in the Chinese population both short or extremely 386 
long telomeres were both found to be risk factors in oesophageal squamous cell carcinoma 387 
(ESCC) [141]. A similar scenario has also been found in glioma and pancreatic adenocarcinoma 388 
[142, 143].  389 
There is a clear need to accurately identify cancer patients with a good or poor clinical outlook 390 
as close to diagnosis as possible, thereby providing important information to patients, their 391 
clinicians and funding agencies, particularly with the advent of expensive targeted therapies. 392 
Telomere length shows great promise as a prognostic and predictive marker for certain 393 
cancers, though the sometimes contrasting results in telomere length association studies 394 
suggests a cautious outlook should be adopted. The influence of telomere length on driving 395 
oncogenesis may differ across cancer types, each with distinct phenotypes resulting in diverse 396 
effects on survival and modulating the prognostic potential of telomere length. Equally, 397 
design study design parameters, experimental approach and analysis method may also 398 
influence the relationship between telomere length and cancer progression [43]. Several 399 
recent meta-analyses of associations between telomere length and cancer prognosis 400 
conclude that standardization of methodology and validation are required, as well as larger 401 
prospective studies of specific cancer types to better evaluate the role of telomere length 402 
before and after cancer diagnosis [22, 144, 145]. 403 
 404 
 405 
Summary 406 
Critically shortened telomeres, rendered dysfunctional by replicative erosion or stochastic 407 
deletion, play a central role in driving oncogenesis by generating genomic rearrangements 408 
that disrupt oncogene or tumor suppressor pathways, and by generating clonal diversity 409 
which fosters genome evolution through natural selection. Recent studies using high-410 
throughput sequencing suggest that the complexity of telomere-induced genome instability 411 
may be have been greatly underappreciated, with extremely convoluted and intricate 412 
genomic configurations now being reported [101, 113, 146]. The importance of telomere 413 
biology to cancer progression has also been emphasized by a growing number of studies 414 
which have correlated short telomere lengths with clinical prognosis. Despite these 415 
considerable achievements, quantifying telomere length dynamics remains technically 416 
challenging, although emerging technologies promise to address these difficulties.   417 
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 766 
  767 
Figure 1. Overview of telomere structure.  768 
The terminal ends of mammalian chromosomes consist of an array of TTAGGGn 769 
repeats ending with a 3’ overhang of between 50 - 300 nt in length (A). This array is 770 
bound by many protein components including members of the shelterin complex that 771 
anchors to the repeat array through Telomere Repeat binding Factors 1 & 2 (TRF1 772 
and TRF2), binding repeats as a homodimer, and forming a complex with TIN2 773 
(TRF1-interacting factor), RAP1 (Repressor Activator Protein 1), TPP1 and POT1 774 
(Protection of Telomere 1) (A). The repeat array folds into a higher order t-loop 775 
structure where the 3’ overhang displaces a portion of the forward strand to create a 776 
d-loop, thereby sequestering the free chromosome end from the DNA repair 777 
machinery (B).  778 
  779 
Figure 2. Cascades of genome rearrangement induced by free chromosome 780 
ends. 781 
Telomeres that lose their capping function can trigger DNA damage signaling and 782 
subsequent processing by DSB repair pathways, instigating genome instability via 783 
several mechanisms. Telomere-telomere (A) fusions create dicentric chromosomes 784 
that may undergo rupture during mitosis, giving rise to a succession of events in a 785 
BFB cycle (i). Alternatively, dicentric chromosomes may be stabilized by centromere 786 
silencing (ii). Dysfunctional telomeres may also undergo joining with internal genomic 787 
loci giving rise to non-reciprocal translocations (B). Depending on the nature of the 788 
join, several outcomes are possible with examples of events given in C&D. One 789 
outcome is the formation of a dicentric chromosome plus an acentric chromosome 790 
(C), which may elicit further BFB events or instability by reintegration of the acentric 791 
chromosome at another genomic site. Alternatively, a functional telomere may be 792 
transferred to the initiating chromosome, at the cost of creating another free end at 793 
the participating chromosome (D). Chromosomes with free ends may be stabilized 794 
by circularization, or through the seeding of a new telomere (ii). Recent reports 795 
suggest that telomere dysfunction may also trigger ‘all-at-once’ events such as 796 
chromothripsis, a process thought to involve the shattering and random re-ligation of 797 
chromosomes that may either give rise to a stable genomic configuration, or may 798 
promote further instability due to the presence of a free chromosome end (iii).  799 
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